Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial

The Lancet Oncology

Volumn 15, Issue 3, 2014, Pages 305-314

  Conroy, Thierry ^a   Galais, Marie Pierre ^b   Raoul, Jean Luc ^c   Bouché, Olivier ^d   Gourgou Bourgade, Sophie ^e   Douillard, Jean Yves ^f   Etienne, Pierre Luc ^g   Boige, Valérie ^h   Martel Lafay, Isabelle ⁱ   Michel, Pierre ^j   Llacer Moscardo, Carmen ^e   François, Eric ^k   Créhange, Gilles ^l   Abdelghani, Meher Ben ^m   Juzyna, Beata ⁿ   Bedenne, Laurent ^o   Adenis, Antoine ^p  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CENTRE FRANÇOIS BACLESSE   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e CENTRE VAL D AURELLE   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g Clinique Armoricaine de Radiologie   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

^j HÔPITAL CHARLES NICOLLE   (France)

^k CENTRE ANTOINE LACASSAGNE   (France)

^l CENTRE GEORGES FRANÇOIS LECLERC   (France)

^m CENTRE PAUL STRAUSS   (France)

ⁿ UNICANCER   (France)

^o HÔPITAL DU BOCAGE   (France)

^p CENTRE OSCAR LAMBRET   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; APHAGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BODY WEIGHT DISORDER; BOLUS INJECTION; CALORIC INTAKE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; DYSPHAGIA; EPIGASTRIC PAIN; ERYTHEMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL ADENOSQUAMOUS CARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS PAIN; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FRANCE; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERKALEMIA; HYPOCALCEMIA; HYPONATREMIA; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NUTRITIONAL DISORDER; ODYNOPHAGIA; OPEN STUDY; PARALLEL DESIGN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RETROSTERNAL PAIN; SENSORY NEUROPATHY; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 84896710018     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70028-2     Document Type: Article

References (36)

1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999, 281:1623-1627.
2. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
3. Wong R, Malthaner R Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006, 1. CD002092.
4. Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(suppl 6):vi51-v565. on behalf of the ESMO Guidelines Working Group.
5. Highley MS, Hill ME, Ziras N, et al. High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma. Br J Cancer 1993, 67:407-408.
6. Stahl M, Wilke H, Meyer HJ, et al. 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. Eur J Cancer 1994, 30A:325-328.
7. Hermann RM, Rave-Fränk M, Pradier O Combining radiation with oxaliplatin: a review of experimental results. Cancer Radiother 2008, 12:61-67.
8. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002, 20:2844-2850.
9. O'Connor BM, Chadha MK, Pande A, et al. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J 2007, 13:119-124.
10. Chiarion-Sileni V, Innocente R, Cavina R, et al. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol 2009, 63:1111-1119.
11. Mauer AM, Kraut EH, Krauss SA, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005, 16:1320-1325.
12. Conroy T, Viret F, François E, et al. Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. Br J Cancer 2008, 99:1395-1401.
13. Conroy T, Yataghène Y, Etienne PL, et al. Phase II randomised trial of chemotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 2010, 103:1349-1355.
14. Sobin LH, Wittekind C Oesophagus (ICD-O C15). UICC TNM classification of malignant tumours 2002, 60-64. Wiley-Liss, New York. 6th edn. L.H. Sobin, C. Wittekind (Eds.).
15. Thomas CR, Berkey BA, Minsky BD, et al. Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 2004, 58:1405-1410.
16. Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol 1992, 10:1037-1043.
17. ICRU Report 50. Prescribing, recording, and reporting photon beam therapy 1993, International Commission on Radiation Units and Measurements (ICRU), ICRU, Bethesda.
18. ICRU Report 62 (supplement to report 50). Prescribing, recording, and reporting photon beam therapy 1999, International Commission on Radiation Units and Measurements (ICRU), ICRU, Bethesda.
19. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
20. Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003, 39:1384-1394.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
22. Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005, 35:316-323.
23. O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
24. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Statist Ass 1958, 53:457-481.
25. Grambsch PM, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
26. Treatment of early breast cancer volume 1: worldwide evidence 1985-1990 1990, Early Breast Cancer Trialists' Collaborative Group, Oxford University Press, Oxford.
27. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013, 14:627-637.
28. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
29. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12:681-692.
30. Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009, 27:3786-3793.
31. Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012, 30:4416-4426.
32. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008, 26:4551-4556.
33. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
34. Wang H, Ryu J, Gandara D, et al. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol 2007, 2:153-157.
35. Ruppert BN, Watkins JM, Shirai K, et al. Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010, 33:346-352.
36. Courrech Staal EF, Aleman BM, van Velthuysen ML, et al. Chemoradiation for esophageal cancer: institutional experience with three different regimens. Am J Clin Oncol 2011, 34:343-349.